Circulating MicroRNAs as Potential Risk Biomarkers for Hematoma Enlargement after Intracerebral Hemorrhage

Hong Wei Zheng, Yi Long Wang, Jin Xi Lin, Na Li, Xing Quan Zhao, Gai Fen Liu, Li Ping Liu, Yan Jiao, Weikuan Gu, David Z. Wang, Yong Jun Wang

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background and Purpose: MicroRNAs have recently been shown to regulate the downstream bioprocesses of intracerebral hemorrhage. The aim of this study was to investigate whether miRNAs can be used as biomarkers to predict secondary hematoma enlargement (HE) in patients with ICH. Methods: Consecutively, 79 ICH patients admitted within 6 h of symptom onset and 30 healthy individuals were enrolled in this study. Whole-genome miRNA expression profiles were generated in 32 patients (HE/non-HE: 14/18). Representative differentially expressed miRNAs were measured in all cases (HE/non-HE: 30/49) and normal controls (n = 30) by real-time PCR. Results: Thirty miRNAs showed differential expressions in the plasma samples from patients with HE as compared with the non-HE controls. Compared to the hierarchical cluster analysis with all probes on microarray, all patients were separated into two main branches with only four exceptions by 30 differentially expressed miRNAs, improving the overall accuracy from 47.62 to 77.78% in the HE and 72.73 to 100% in the non-HE group. Further support vector machine (SVM) test can discriminate the two groups with 100% accuracy with 10 differentially expressed miRNAs. Conclusions: We demonstrated that multiple miRNAs are differentially expressed in the plasma of ICH patients with or without HE and may serve as circulating biomarkers for predicting HE after ICH.

Original languageEnglish (US)
Pages (from-to)1003-1011
Number of pages9
JournalCNS Neuroscience and Therapeutics
Volume18
Issue number12
DOIs
StatePublished - Dec 1 2012

Fingerprint

Cerebral Hemorrhage
MicroRNAs
Hematoma
Biomarkers
Cluster Analysis
Real-Time Polymerase Chain Reaction
Genome

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Psychiatry and Mental health
  • Physiology (medical)
  • Pharmacology (medical)

Cite this

Zheng, H. W., Wang, Y. L., Lin, J. X., Li, N., Zhao, X. Q., Liu, G. F., ... Wang, Y. J. (2012). Circulating MicroRNAs as Potential Risk Biomarkers for Hematoma Enlargement after Intracerebral Hemorrhage. CNS Neuroscience and Therapeutics, 18(12), 1003-1011. https://doi.org/10.1111/cns.12019

Circulating MicroRNAs as Potential Risk Biomarkers for Hematoma Enlargement after Intracerebral Hemorrhage. / Zheng, Hong Wei; Wang, Yi Long; Lin, Jin Xi; Li, Na; Zhao, Xing Quan; Liu, Gai Fen; Liu, Li Ping; Jiao, Yan; Gu, Weikuan; Wang, David Z.; Wang, Yong Jun.

In: CNS Neuroscience and Therapeutics, Vol. 18, No. 12, 01.12.2012, p. 1003-1011.

Research output: Contribution to journalArticle

Zheng, HW, Wang, YL, Lin, JX, Li, N, Zhao, XQ, Liu, GF, Liu, LP, Jiao, Y, Gu, W, Wang, DZ & Wang, YJ 2012, 'Circulating MicroRNAs as Potential Risk Biomarkers for Hematoma Enlargement after Intracerebral Hemorrhage', CNS Neuroscience and Therapeutics, vol. 18, no. 12, pp. 1003-1011. https://doi.org/10.1111/cns.12019
Zheng, Hong Wei ; Wang, Yi Long ; Lin, Jin Xi ; Li, Na ; Zhao, Xing Quan ; Liu, Gai Fen ; Liu, Li Ping ; Jiao, Yan ; Gu, Weikuan ; Wang, David Z. ; Wang, Yong Jun. / Circulating MicroRNAs as Potential Risk Biomarkers for Hematoma Enlargement after Intracerebral Hemorrhage. In: CNS Neuroscience and Therapeutics. 2012 ; Vol. 18, No. 12. pp. 1003-1011.
@article{329c4122e4894fc3bc4ddd0d77faccd4,
title = "Circulating MicroRNAs as Potential Risk Biomarkers for Hematoma Enlargement after Intracerebral Hemorrhage",
abstract = "Background and Purpose: MicroRNAs have recently been shown to regulate the downstream bioprocesses of intracerebral hemorrhage. The aim of this study was to investigate whether miRNAs can be used as biomarkers to predict secondary hematoma enlargement (HE) in patients with ICH. Methods: Consecutively, 79 ICH patients admitted within 6 h of symptom onset and 30 healthy individuals were enrolled in this study. Whole-genome miRNA expression profiles were generated in 32 patients (HE/non-HE: 14/18). Representative differentially expressed miRNAs were measured in all cases (HE/non-HE: 30/49) and normal controls (n = 30) by real-time PCR. Results: Thirty miRNAs showed differential expressions in the plasma samples from patients with HE as compared with the non-HE controls. Compared to the hierarchical cluster analysis with all probes on microarray, all patients were separated into two main branches with only four exceptions by 30 differentially expressed miRNAs, improving the overall accuracy from 47.62 to 77.78{\%} in the HE and 72.73 to 100{\%} in the non-HE group. Further support vector machine (SVM) test can discriminate the two groups with 100{\%} accuracy with 10 differentially expressed miRNAs. Conclusions: We demonstrated that multiple miRNAs are differentially expressed in the plasma of ICH patients with or without HE and may serve as circulating biomarkers for predicting HE after ICH.",
author = "Zheng, {Hong Wei} and Wang, {Yi Long} and Lin, {Jin Xi} and Na Li and Zhao, {Xing Quan} and Liu, {Gai Fen} and Liu, {Li Ping} and Yan Jiao and Weikuan Gu and Wang, {David Z.} and Wang, {Yong Jun}",
year = "2012",
month = "12",
day = "1",
doi = "10.1111/cns.12019",
language = "English (US)",
volume = "18",
pages = "1003--1011",
journal = "CNS Neuroscience and Therapeutics",
issn = "1755-5930",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Circulating MicroRNAs as Potential Risk Biomarkers for Hematoma Enlargement after Intracerebral Hemorrhage

AU - Zheng, Hong Wei

AU - Wang, Yi Long

AU - Lin, Jin Xi

AU - Li, Na

AU - Zhao, Xing Quan

AU - Liu, Gai Fen

AU - Liu, Li Ping

AU - Jiao, Yan

AU - Gu, Weikuan

AU - Wang, David Z.

AU - Wang, Yong Jun

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Background and Purpose: MicroRNAs have recently been shown to regulate the downstream bioprocesses of intracerebral hemorrhage. The aim of this study was to investigate whether miRNAs can be used as biomarkers to predict secondary hematoma enlargement (HE) in patients with ICH. Methods: Consecutively, 79 ICH patients admitted within 6 h of symptom onset and 30 healthy individuals were enrolled in this study. Whole-genome miRNA expression profiles were generated in 32 patients (HE/non-HE: 14/18). Representative differentially expressed miRNAs were measured in all cases (HE/non-HE: 30/49) and normal controls (n = 30) by real-time PCR. Results: Thirty miRNAs showed differential expressions in the plasma samples from patients with HE as compared with the non-HE controls. Compared to the hierarchical cluster analysis with all probes on microarray, all patients were separated into two main branches with only four exceptions by 30 differentially expressed miRNAs, improving the overall accuracy from 47.62 to 77.78% in the HE and 72.73 to 100% in the non-HE group. Further support vector machine (SVM) test can discriminate the two groups with 100% accuracy with 10 differentially expressed miRNAs. Conclusions: We demonstrated that multiple miRNAs are differentially expressed in the plasma of ICH patients with or without HE and may serve as circulating biomarkers for predicting HE after ICH.

AB - Background and Purpose: MicroRNAs have recently been shown to regulate the downstream bioprocesses of intracerebral hemorrhage. The aim of this study was to investigate whether miRNAs can be used as biomarkers to predict secondary hematoma enlargement (HE) in patients with ICH. Methods: Consecutively, 79 ICH patients admitted within 6 h of symptom onset and 30 healthy individuals were enrolled in this study. Whole-genome miRNA expression profiles were generated in 32 patients (HE/non-HE: 14/18). Representative differentially expressed miRNAs were measured in all cases (HE/non-HE: 30/49) and normal controls (n = 30) by real-time PCR. Results: Thirty miRNAs showed differential expressions in the plasma samples from patients with HE as compared with the non-HE controls. Compared to the hierarchical cluster analysis with all probes on microarray, all patients were separated into two main branches with only four exceptions by 30 differentially expressed miRNAs, improving the overall accuracy from 47.62 to 77.78% in the HE and 72.73 to 100% in the non-HE group. Further support vector machine (SVM) test can discriminate the two groups with 100% accuracy with 10 differentially expressed miRNAs. Conclusions: We demonstrated that multiple miRNAs are differentially expressed in the plasma of ICH patients with or without HE and may serve as circulating biomarkers for predicting HE after ICH.

UR - http://www.scopus.com/inward/record.url?scp=84870451897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870451897&partnerID=8YFLogxK

U2 - 10.1111/cns.12019

DO - 10.1111/cns.12019

M3 - Article

VL - 18

SP - 1003

EP - 1011

JO - CNS Neuroscience and Therapeutics

JF - CNS Neuroscience and Therapeutics

SN - 1755-5930

IS - 12

ER -